Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
July 2021
in “
Pharmaceutics
”
TLDR Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
The article discussed the development of ruxolitinib cream, a selective JAK1/2 inhibitor designed for targeted local delivery to treat immune-mediated dermatologic diseases. The JAK signaling pathway was crucial for inflammatory cytokine signaling, and ruxolitinib was developed with low nanomolar potency specific to JAK1 and 2, minimizing effects on non-JAK kinases. Incyte Corporation formulated an oil-in-water emulsified cream for topical use, which was studied in conditions like psoriasis, alopecia areata, atopic dermatitis, and vitiligo. This cream represented a novel approach to directly treat cytokine-driven inflammatory skin diseases.